Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modeling in Therapy01:26

Modeling in Therapy

89
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
89
Behavior Therapy01:22

Behavior Therapy

54
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
54
Tumor Immunotherapy01:27

Tumor Immunotherapy

530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Open forum infectious diseases·2026
Same author

Autoantigen-loaded Polymeric Microparticles associate with B cells and promote tolerogenic antigen presentation in a mouse model of experimental autoimmune encephalomyelitis.

Nature communications·2026
Same author

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.

AME clinical trials review·2026
Same author

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Blood cancer journal·2026
Same author

High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

Blood·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026

Related Experiment Video

Updated: Jul 11, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Building safety into CAR-T therapy.

Daniel T Peters1, Barbara Savoldo2, Natalie S Grover3

  • 1Department of Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Human Vaccines & Immunotherapeutics
|November 15, 2023
PubMed
Summary

Chimeric antigen receptor T cell (CAR-T) therapy shows promise for blood cancers but causes toxicities. New safety measures are crucial, especially for solid tumor applications, with inducible Caspase 9 offering a potential solution.

Keywords:
CAR-TCRSICANScellular therapyinducible caspase 9safety switch

More Related Videos

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle
14:57

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle

Published on: January 30, 2019

13.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
Structural Design and Manufacturing of a Cruiser Class Solar Vehicle
14:57

Structural Design and Manufacturing of a Cruiser Class Solar Vehicle

Published on: January 30, 2019

13.9K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Chimeric antigen receptor T cell (CAR-T) therapy is a groundbreaking immunotherapy utilizing genetically engineered T-cells for cancer treatment.
  • CAR-T therapy has demonstrated significant efficacy in relapsed/refractory B-cell malignancies and is expanding into other hematologic and solid tumors.

Purpose of the Study:

  • To review the development of CAR-T therapy, its associated toxicities, and strategies for mitigation.
  • To explore the unique safety challenges in applying CAR-T therapy to solid tumors.
  • To highlight the inducible Caspase 9 safety switch as a platform for safer CAR-T exploration.

Main Methods:

  • Review of existing literature on CAR-T therapy, its clinical applications, and toxicities.
  • Analysis of safety management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
  • Examination of challenges and potential solutions for CAR-T therapy in solid tumors, including safety switch technologies.

Main Results:

  • CAR-T therapy has achieved success in B-cell malignancies but is associated with significant toxicities like CRS, ICANS, and on-target off-tumor effects.
  • Improvements in managing CRS and ICANS exist, yet refractory symptoms and unpredictable toxicities persist, particularly as CAR-T is explored in solid tumors.
  • The inducible Caspase 9 safety switch presents a promising platform for enhancing the safety of CAR-T cell therapy.

Conclusions:

  • CAR-T therapy is a powerful tool with evolving safety concerns.
  • Enhanced safety measures are imperative for the continued expansion of CAR-T therapy, especially in solid tumors.
  • The inducible Caspase 9 system offers a viable strategy to improve CAR-T therapy safety and facilitate broader clinical application.